{"text": "with 1 5b sage deal biogen bolsters phase iii pipeline ahead of aducanumab decision how will biib and sage partner to ensure phase iii mdd amp ppd asset zuranolone makes it to market"}
{"text": "our downgrade to market perform is based upon our view that the now captive zuranolone program has made sage a catch 22 investment around the outcome with biogens aducanumab sage biib"}
{"text": "on the second front biib provided a relatively weak argument for their ability to build a presence within the field of psychiatry the analysts wrote"}
{"text": "raymond james analysts downgrading sage to market perform writing that this morning s investor calls which were meant to inspire confidence in the deal with biib failed on two fronts"}
{"text": "top 3 today by web traffic 1 with aducanumab caught on a cliff biogens michel vounatsos bets billions on another high risk neuro play biib"}
{"text": "biib biogen taking a closer look at the biib sage deal equity stocks"}
